mesothelioma Archives -

Bristol-Myers Squibb’s immunotherapy combination of Opdivo and Yervoy has been approved in the US in a new indication

FDA approves BMS’ Opdivo and Yervoy combination in first-line mesothelioma

https://pharmaphorum.com/news/fda-approves-bms-opdivo-and-yervoy-combination-in-first-line-mesothelioma/

Bristol-Myers Squibb’s Opdivo has improved survival in a trial involving patients with mesothelioma, a form of lung cancer,

BMS’ Opdivo aces trial in asbestos-linked lung cancer

https://pharmaphorum.com/news/bms-opdivo-aces-trial-in-asbestos-linked-lung-cancer/

A mesothelioma prognostic model from medical machine learning firm Owkin has been showcased in the journal Nature, and

Owkin’s machine learning tech to inform mesothelioma trials

https://pharmaphorum.com/news/owkins-machine-learning-tech-gives-mesothelioma-prognosis-and-survival-insights/

Boehringer Ingelheim is the latest company to gain a Promising Innovative Medicine (PIM) status in the UK for

BI drug named Promising Innovative Medicine in mesothelioma

https://pharmaphorum.com/news/bi-drug-named-promising-innovative-medicine-mesothelioma/

mesothelioma